Year: 2020
Type: Article
Title: Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
Author: Rroji, Merita
Author: Figurek, Andreja
Author: Spasovski, Goce
Abstract: Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.
Publisher: MDPI AG
Relation: Toxins
Identifier: oai:repository.ukim.mk:20.500.12188/18543
Identifier: http://hdl.handle.net/20.500.12188/18543Identifier: 10.3390/toxins12030140
Identifier: https://www.mdpi.com/2072-6651/12/3/140/pdfIdentifier: 12
Identifier: 3
